SCHEDULE: Affinity Asset Advisors Discloses 9% Stake in Ventyx Bioscience

Affinity Asset Advisors, LLC and Michael Cho have reported a 9% beneficial ownership stake in Ventyx Bioscience, Inc. common stock.

Summary

• Affinity Asset Advisors, LLC and Michael Cho reported beneficial ownership of 6,465,041 shares of Ventyx Bioscience, Inc. common stock.
• This represents approximately 9.0% of the outstanding common stock of Ventyx Bioscience, Inc.
• The ownership includes 5,665,041 shares of common stock directly held by Affinity Healthcare Fund, LP, and listed call options exercisable for an additional 800,000 shares.
• Affinity Asset Advisors, LLC acts as the investment manager for Affinity Healthcare Fund, LP, with Michael Cho as its managing member.
• The percentage is based on 71,750,148 shares of Ventyx Bioscience, Inc. common stock outstanding as of December 31, 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as a significant institutional stake can signal investor confidence and potentially attract further institutional interest, despite a minor reduction in total shares from a prior period.

Positives

• A significant institutional investor, Affinity Asset Advisors, LLC, has disclosed a 9% stake, potentially signaling confidence in Ventyx Bioscience, Inc.
• The investment includes both direct stock holdings and call options, indicating a bullish outlook on the stock's future performance.

Negatives

• The filing indicates a slight reduction in beneficial ownership from 6,484,558 shares as of December 31, 2025, to 6,465,041 shares as of the filing date, though the percentage of class remains 9%.

Risks

• The filing does not detail specific risks related to Ventyx Bioscience, Inc.'s operations or financial health.
• The investment is subject to market fluctuations inherent in equity and options holdings.

Future Outlook

The filing does not contain any forward-looking statements or guidance from Ventyx Bioscience, Inc. or the reporting persons regarding the issuer's future performance.

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

StockSavvy.ai notes that significant institutional ownership disclosures, such as this 13G filing, are common in the biotechnology sector, where specialized funds often take substantial positions in promising companies. This filing indicates continued institutional interest in Ventyx Bioscience, Inc.

Comparison to Industry Standards

• A 9% stake by an investment advisor like Affinity Asset Advisors is a substantial position, often seen as a vote of confidence, particularly in growth-oriented sectors like biotechnology. For instance, similar significant stakes have been observed in other emerging biotech firms where specialized funds like ARK Invest or Perceptive Advisors build positions, often preceding periods of increased market attention or strategic developments.
• The inclusion of call options in the beneficial ownership calculation is a common strategy for funds seeking leveraged exposure or expressing a strong bullish view, similar to how funds might use derivatives in other high-growth sectors to enhance returns or manage risk.

Stakeholder Impact

• Shareholders: Increased institutional ownership may be viewed positively, potentially leading to increased liquidity and investor confidence.
• Company Management: A significant shareholder may exert influence, though the filing states the purpose is not to change or influence control, except for potential nominations under Rule 14a-11.

Next Steps

• Ventyx Bioscience, Inc. will continue its operations.
• Affinity Asset Advisors, LLC and Michael Cho will continue to manage their investment in Ventyx Bioscience, Inc.
• Further Schedule 13G amendments would be filed if beneficial ownership changes significantly (e.g., crosses a 1% threshold).

Key Dates

Recommendation

The disclosure of a 9% beneficial ownership by Affinity Asset Advisors, LLC is a positive signal of institutional confidence in Ventyx Bioscience, Inc. However, the filing itself does not provide new operational or financial performance data to warrant a 'buy' recommendation. The slight reduction in shares from the prior period, while maintaining the 9% threshold, suggests a stable but not aggressively increasing position. Investors should 'hold' and monitor future company performance and any further changes in institutional ownership.

Keywords

Ventyx Bioscience, Affinity Asset Advisors, Michael Cho, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Equity Stake, Biotechnology, Healthcare Fund